The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas
Open accessAbstract
INTRODUCTION: Highly aggressive thoracic neoplasms characterized by SMARCA4 (BRG1) deficiency and undifferentiated round cell or rhabdoid morphology have been recently described and proposed to represent thoracic sarcomas. However, it remains unclear whether such tumors may instead represent sarcomatoid carcinomas, and how their clinicopathologic characteristics compare with those of nonsarcomatoid SMARCA4-deficient non-small cell lung carcinomas (SD-NSCC). METHODS: We identified 22 SMARCA4-deficient thoracic sarcomatoid tumors (SD-TSTs) with round cell and/or rhabdoid morphology and 45 SD-NSCCs, and comprehensively analyzed their clinicopathologic, immunohistochemical, and genomic characteristics using 341-468 gene next-generation sequencing and other molecular platforms. RESULTS: The relationship of SD-TSTs with NSCC was supported by (1) the presence of NSCC components juxtaposed with sarcomatoid areas in five cases, (2) focal expression of NSCC lineage markers TTF1 or p40 in four additional cases, (3) smoking history in all except one patient (mean = 51 pack-years), accompanied by genomic smoking signature, and (4) high tumor mutation burden (mean = 14.2 mutations per megabase) and mutations characteristic of NSCC in a subset. Compared with SD-NSCCs, SD-TSTs exhibited considerably larger primary tumor size (p < 0.0001), worse survival (p = 0.004), and more frequent presentation at younger age (30-50 years) despite heavier smoking history. Distinctive pathologic features of SD-TSTs included consistent lack of adhesion molecule claudin-4, SMARCA2 (BRM) codeficiency, and frequent expression of stem cell markers. CONCLUSIONS: SD-TSTs represent primarily smoking-associated undifferentiated/de-differentiated carcinomas rather than primary thoracic sarcomas. Despite their histogenetic relationship with NSCC, these tumors have unique clinicopathologic characteristics, supporting their recognition as a distinct entity. Further studies are warranted to determine therapeutic approaches to this novel class of exceptionally aggressive thoracic tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“Using NGS results, all silent and nonsilent mutations were used to identify different mutational signatures according to the distribution of the six substitution classes (C>A, C>G, C>T, T>A, T>C, T>G) and their trinucleotide context; for each sample, a weight corresponding to the percentage of mutations explained by e…”
MethodSelf-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationZehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 4×
“next-generation sequencing (NGS) results.(27,28) Third, five cases were identified by means of a retrospective search of pathology database for unclassified undifferentiated thoracic tumors in patients who are below 40 years or whose pathology reports contained search terms “rhabdoid,” “NUT,” or “SMARCB1/INI1/BAF47.”
BackgroundMethodInfluentialSelf-citationWHO classification of tumours of the lung, pleura, thymus and heart
Travis, W. D. (2015) · International Agency for Research on Cancer eBooks · Cited by 1,664
Self-citationSWI/SNF nucleosome remodellers and cancer
Wilson, B. G., & Roberts, C. W. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3068 · Cited by 1,282
Shen, R., & Seshan, V. E. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw520 · Cited by 1,258
Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas
Abeshouse, A., Adebamowo, C., Adebamowo, S. N., Akbani, R., Akeredolu, T., Ally, A., Anderson, M. L., Anur, P., Appelbaum, E. L., Armenia, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.014 · Cited by 1,069
Self-citationJordan, E. J., Kim, H. R., Arcila, M. E., Barron, D., Chakravarty, D., Gao, J., Chang, M. T., Ni, A., Kundra, R., Jonsson, P., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1337 · Cited by 643
Self-citationThe SWI/SNF complex — chromatin and cancer
Roberts, C. W. M., & Orkin, S. H. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1273 · Cited by 603
Witkowski, L., Carrot-Zhang, J., Albrecht, S., Fahiminiya, S., Hamel, N., Tomiak, E., Grynspan, D., Saloustros, E., Nadaf, J., Rivera, B., et al. (2014) · Nature Genetics · doi:10.1038/ng.2931 · Cited by 501
INI1-Deficient Tumors: Diagnostic Features and Molecular Genetics
Hollmann, T. J., & Hornick, J. L. (2011) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31822b325b · Cited by 427
Weeks, D. A., Beckwith, J. B., Mierau, G. W., & Luckey, D. W. (1989) · PubMed · Cited by 400
Ramos, P., Karnezis, A. N., Craig, D. W., Sekulic, A., Russell, M. L., Hendricks, W. P. D., Corneveaux, J. J., Barrett, M. T., Shumansky, K., Yang, Y., et al. (2014) · Nature Genetics · doi:10.1038/ng.2928 · Cited by 387
Le Loarer, F., Watson, S., Pierron, G., de Montpreville, V. T., Ballet, S., Firmin, N., Auguste, A., Pissaloux, D., Boyault, S., Paindavoine, S., et al. (2015) · Nature Genetics · doi:10.1038/ng.3399 · Cited by 378
Reisman, D., Sciarrotta, J., Wang, W., Funkhouser, W. K., & Weissman, B. E. (2003) · PubMed · Cited by 378
Schneppenheim, R., Frühwald, M. C., Gesk, S., Hasselblatt, M., Jeibmann, A., Kordes, U., Kreuz, M., Leuschner, I., Subero, J. I. M., Obser, T., et al. (2010) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2010.01.013 · Cited by 348
Yoshida, A., Kobayashi, E., Kubo, T., Kodaira, M., Motoi, T., Motoi, N., Yonemori, K., Ohe, Y., WATANABE, S.-I. I., Kawai, A., et al. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.11 · Cited by 233
Silva, E. G., Deavers, M. T., Bodurka, D. C., & Malpica, A. (2006) · International Journal of Gynecological Pathology · doi:10.1097/01.pgp.0000183048.22588.18 · Cited by 232
Karnezis, A. N., Wang, Y., Ramos, P., Hendricks, W. P., Oliva, E., D'Angelo, E., Prat, J., Nucci, M. R., Nielsen, T. O., Chow, C., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4633 · Cited by 217
Sauter, J. L., Graham, R. P., Larsen, B. T., Jenkins, S. M., Roden, A. C., & Boland, J. M. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.61 · Cited by 197
Self-citationTorchia, J., Picard, D., Lafay-Cousin, L., Hawkins, C. E., Kim, S.-K., Letourneau, L., Ra, Y.-S., Ho, K. C., Chan, T. S. Y., Sin-Chan, P., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70114-2 · Cited by 182
Agaimy, A. (2014) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000038 · Cited by 163
Bell, E. H., Chakraborty, A. R., Mo, X. M., Liu, Z., Shilo, K., Kirste, S., Stegmaier, P., McNulty, M., Karachaliou, N., Rosell, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1468 · Cited by 148
Matsubara, D., Kishaba, Y., Ishikawa, S., Sakatani, T., Oguni, S., Tamura, T., Hoshino, H., Sugiyama, Y., Endo, S., Murakami, Y., et al. (2012) · Cancer Science · doi:10.1111/cas.12065 · Cited by 134
Foulkes, W. D., Clarke, B. A., Hasselblatt, M., Majewski, J., Albrecht, S., & McCluggage, W. G. (2014) · The Journal of Pathology · doi:10.1002/path.4362 · Cited by 125
SMARCB1 (INI1)-negative Rhabdoid Carcinomas of the Gastrointestinal Tract
Agaimy, A., Rau, T. T., Hartmann, A., & Stoehr, R. (2014) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000173 · Cited by 116
Rekhtman, N., Tafe, L. J., Chaft, J. E., Wang, L., Arcila, M. E., Colanta, A., Moreira, A. L., Zakowski, M. F., Travis, W. D., Sima, C. S., et al. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.195 · Cited by 113
Self-citationHenon, C., Blay, J., Massard, C., Mir, O., Bahleda, R., Dumont, S., Postel-Vinay, S. C., Adam, J., Soria, J., & Cesne, A. L. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz160 · Cited by 113
Clinical and Molecular Characteristics of NF1 -Mutant Lung Cancer
Redig, A. J., Capelletti, M., Dahlberg, S. E., Sholl, L. M., Mach, S. L., Fontes, C., Shi, Y., Chalasani, P., & Janne, P. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2377 · Cited by 84
Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma
Tanaka, K., Hida, T., Oya, Y., Yoshida, T., Shimizu, J., Mizuno, T., Kuroda, H., Sakakura, N., Yoshimura, K., Horio, Y., et al. (2017) · Cancer · doi:10.1002/cncr.30539 · Cited by 74
Hereditary SWI/SNF complex deficiency syndromes
Agaimy, A., & Foulkes, W. D. (2018) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2018.01.002 · Cited by 67
Orlando, K. A., Nguyen, V. Q., Raab, J. R., Walhart, T. A., & Weissman, B. E. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1605905 · Cited by 57
Lin, D. I., Chudnovsky, Y., Duggan, B., Zajchowski, D. A., Greenbowe, J. R., Ross, J. S., Gay, L. M., Ali, S. M., & Elvin, J. A. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.09.031 · Cited by 54
Yoshimoto, T., Matsubara, D., Nakano, T., Tamura, T., Endo, S., Sugiyama, Y., & Niki, T. (2015) · Pathology International · doi:10.1111/pin.12350 · Cited by 51
BAFfling pathologies: Alterations of BAF complexes in cancer
Arnaud, O., Loarer, F. L., & Tirode, F. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.046 · Cited by 49
Abro, B., Kaushal, M., Chen, L., Wu, R. C., Dehner, L. P., Pfeifer, J. D., & He, M. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.03.023 · Cited by 32
Cited by
Rudin, C. M., Brambilla, E., Faivre-Finn, C., & Sage, J. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00235-0 · Cited by 1,570
Self-citationThe 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
Nicholson, A. G., Tsao, M. S., Beasley, M. B., Borczuk, A. C., Brambilla, E., Cooper, W. A., Dacic, S., Jain, D., Kerr, K. M., Lantuejoul, S., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.11.003 · Cited by 1,554
Self-citationOverview of the 2022 WHO Classification of Neuroendocrine Neoplasms
Rindi, G., Mete, O., Uccella, S., Basturk, O., La Rosa, S., Brosens, L. A. A., Ezzat, S., de Herder, W. W., Klimstra, D. S., Papotti, M., et al. (2022) · Endocrine Pathology · doi:10.1007/s12022-022-09708-2 · Cited by 1,036
Schoenfeld, A. J., Bandlamudi, C., Lavery, J. A., Montecalvo, J., Namakydoust, A., Rizvi, H., Egger, J., Concepcion, C. P., Paul, S., Arcila, M. E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1825 · Cited by 296
Self-citation
Metadata
- Authors
- Rekhtman, N., Montecalvo, J., Chang, J. C., Alex, D., Ptashkin, R. N., Ai, N., Sauter, J. L., Kezlarian, B., Jungbluth, A., Desmeules, P., Beras, A., Bishop, J. A., Plodkowski, A. J., Gounder, M. M., Schoenfeld, A. J., Namakydoust, A., Li, B. T., Rudin, C. M., Riely, G. J., Jones, D. R., Ladanyi, M., & Travis, W. D.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 15
- Issue
- 2
- Pages
- 231-247
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2983766759
- Cited by
- 326
- References
- 38
- FWCI
- 8.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.